Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Jun 28, 2014; 6(6): 301-312
Published online Jun 28, 2014. doi: 10.4329/wjr.v6.i6.301
Published online Jun 28, 2014. doi: 10.4329/wjr.v6.i6.301
Neuroimaging in Huntington’s disease
Flavia Niccolini, Marios Politis, Neurodegeneration Imaging Group, Department of Clinical Neuroscience, King’s College London, London SE5 8AF, United Kingdom
Flavia Niccolini, Marios Politis, Division of Brain Sciences, Department of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, United Kingdom
Author contributions: Niccolini F collected the materials for the literature review and wrote the first draft of the manuscript; Politis M reviewed and edited this article.
Correspondence to: Marios Politis, MD, MSc, PhD, Senior Clinical Lecturer, Head of the Neurodegeneration Imaging Group, Department of Clinical Neuroscience, King’s College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom. marios.politis@kcl.ac.uk
Telephone: +44-207-8485682 Fax: +44-207-8480988
Received: December 11, 2013
Revised: February 28, 2014
Accepted: May 8, 2014
Published online: June 28, 2014
Revised: February 28, 2014
Accepted: May 8, 2014
Published online: June 28, 2014
Core Tip
Core tip: Huntington’s disease (HD) is a hereditary and fatal neurodegenerative disorder. Although advances in genetics allow identification of individuals carrying the HD gene, much is still unknown about the mechanisms underlying the development of overt clinical symptoms and the transitional period between premanifestation and manifestation of the disease. Neuroimaging techniques such as magnetic resonance imaging and positron emission tomography may be a suitable biomarker for monitoring disease progression in HD and for assessing the efficacy of future disease modifying therapies. In this article, we provide an overview of the findings from neuroimaging techniques in HD.